Fragment 176-191
Also known as: GH Fragment 176-191, HGH Frag 176-191, AOD-9401
Overview
Fragment 176-191 refers to the unmodified C-terminal peptide fragment of human growth hormone spanning amino acids 176-191. It is the precursor compound from which AOD-9604 was developed via a stabilizing tyrosine modification. Research suggests antilipogenic activity primarily through inhibition of fat formation rather than direct lipolysis stimulation, representing a slightly different activity profile than AOD-9604.
Mechanism of Action
Similar to AOD-9604 but without the tyrosine modification. In vitro rat adipose tissue studies demonstrate antilipogenic activity—reduction in fat storage enzyme activity—with less direct lipolytic activity than the full GH molecule or AOD-9604. Mechanistically interacts with beta-adrenergic pathways in adipose tissue and does not activate GH receptors or stimulate IGF-1.
Potential Benefits
- Antilipogenic properties in preclinical adipose models
- No growth-promoting or IGF-1 stimulating effects
- Potential body composition improvement
- Selective targeting of fat metabolism without systemic GH effects
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | 250 mcg once daily, AM fasted |
| Intermediate | 250-500 mcg 2x daily |
| Advanced | 500 mcg 3x daily |
| Cycle Duration | 8-12 weeks |
Best results on empty stomach. Does not stimulate GH — acts directly on lipolysis. No effect on IGF-1.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection High — standard route
Inject into abdominal fat for theoretical localized lipolysis.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Fragment 176-191:
Fat Loss Stack
Fragment for direct lipolysis + GHRH/GHRP combo for broader GH effects. Fragment 500 mcg AM fasted, CJC/Ipa 100 mcg each pre-bed.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Refrigerate at 2-8°C after reconstitution. Do not freeze reconstituted solution. |
|---|
Typical vial sizes: 2 mg, 5 mg. Add bac water slowly down the side of the vial, swirl gently — do not shake. Use insulin syringe for precise dosing.
Need exact syringe measurements?
Amino Acid Sequence
Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
Side Effects & Safety
- Limited human safety data
- Injection site reactions
- Theoretical endocrine effects
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Active Malignancy
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Pharmacokinetics
| Half-Life | ~30 minutes |
|---|---|
| Storage | Store lyophilized peptide at -20°C (long-term) or 2-8°C (short-term, under 30 days). Reconstituted: refrigerate at 2-8°C and use within 28-30 days. Protect from light. Do not freeze reconstituted solution. |
Synergistic Compounds
The following compounds have been studied alongside Fragment 176-191 for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA PCAC July 2026: What the BPC-157 peptide compounding review really means
FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. What that process means for BPC-157—and what it doesn’t.
FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine
The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack down on advertising that calls them generic versions of branded drugs.
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.